Terazosin for Dementia With Lewy Bodies

This study is testing a drug called Terazosin Hydrochloride to see if it is safe and well-tolerated for people with Dementia With Lewy Bodies (DLB). Participants will be randomly assigned to receive either Terazosin Hydrochloride or a placebo (an inactive substance) for 15 weeks. The study is looking at how often side effects occur and how many people stop the treatment. It also aims to understand how DLB affects the brain's energy use and if Terazosin can help. You may be able to join if you have a diagnosis of DLB, are between 0 and 90 years old, and meet other specific health criteria. The current recruitment status is unclear.

Study design: This is a randomized, double-blind, placebo-controlled pilot study. It plans to enroll 40 participants, with more receiving Terazosin than placebo.
What's involved: Participants will receive either Terazosin Hydrochloride or placebo for 15 weeks, starting at 1mg daily and increasing to 5mg daily. Brain energy levels will be measured at the beginning, at 6 weeks, and at 15 weeks.
Compensation: Not stated in the trial record.
Follow-up: The study measures outcomes for 15 weeks, which is the duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Terazosin for Dementia With Lewy Bodies

Not Yet Recruiting

PHASE1Ages 0–90InterventionalTreatment

Qiang Zhang

~40 participants

Updated 2026-03-12 on ClinicalTrials.gov

What's tested:Terazosin HydrochloridePlacebo

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Incidence of intervention-related adverse events between treatment arms

Measured over 15 weeks

+2 more outcomes measured

Conditions

Dementia With Lewy Bodies

NCT04760860

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

University of Iowa
Iowa City, Iowastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Nandakumar Narayanan, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Iowa

Who to contact

qiang zhang, MD

[email protected]

4154251369

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Men or women with the diagnosis of dementia with Lewy Bodies per 2017 DLB Consortium criteria.

Baseline MOCA 18 or above. On stable AChEI and/or memantine treatment regimen for ≥4 weeks prior to baseline.

Exclusion

Subjects unwilling or unable to give informed consent

No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age-related illness will be included if their disease under control with stable treatment regimen for at least 30 days.

Orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic on supine to sitting or standing, or a sitting blood pressure of ≤90/60.

Clinically significant traumatic brain injury or post-traumatic stress disorder

Presence of other known medical comorbidities that in the investigator's opinion would compromise participation in the study

Psychiatric comorbidities including major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neurology assessment in the opinion of the responsible site principal investigator. Subjects with clinically significant depression as determined by a Beck Depression Inventory score greater than 21 at the screening visit. Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) If the participant has a Beck Anxiety Score greater than 22 at the initial screening visit.

Use of investigational drugs within 30 days before screening

Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to the baseline visit

Use of doxazosin, alfuzosin, prazosin, or tamsulosin

For female participant, pregnancy, or plans for child-bearing during study period

Participant is restricted from traveling to and from the study site

What this trial measures

Incidence of intervention-related adverse events between treatment arms15 weeks
All patient-reported adverse events will be compared.
Frequency of drop-out/discontinuation of study intervention for any reason15 weeks
The number of participants in each group who drop out of the study for any reason will be compared.
Brain [ATP] as measured by 31P-Magnetic Resonance Spectroscopyat baseline, 6 weeks and 15 weeks
Brain \[ATP\] as measured by 31P-Magnetic Resonance Spectroscopy

Trialytics